Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $111.00

Moderna (NASDAQ:MRNA) had its price objective dropped by research analysts at Barclays from $125.00 to $111.00 in a report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 137.03% from the company’s current price.

A number of other brokerages have also weighed in on MRNA. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. TD Cowen decreased their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Leerink Partners dropped their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research report on Tuesday, September 17th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $93.18.

Moderna Stock Down 6.9 %

MRNA stock opened at $46.83 on Friday. The stock has a 50-day simple moving average of $61.85 and a two-hundred day simple moving average of $99.16. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $18.00 billion, a PE ratio of -3.04 and a beta of 1.69. Moderna has a twelve month low of $46.57 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.39) EPS. On average, equities analysts predict that Moderna will post -9.89 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,184 shares of company stock worth $238,531 in the last ninety days. 15.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. boosted its stake in shares of Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares in the last quarter. Profund Advisors LLC lifted its holdings in Moderna by 20.9% in the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after buying an additional 9,719 shares during the period. Tobam boosted its position in Moderna by 121.6% during the 3rd quarter. Tobam now owns 27,794 shares of the company’s stock valued at $1,857,000 after acquiring an additional 15,249 shares in the last quarter. Swedbank AB grew its holdings in shares of Moderna by 149.6% during the 3rd quarter. Swedbank AB now owns 85,099 shares of the company’s stock worth $5,687,000 after acquiring an additional 51,000 shares during the period. Finally, Marshall Wace LLP raised its position in shares of Moderna by 295.5% in the 2nd quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock worth $4,180,000 after acquiring an additional 26,300 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.